Introduction {#Sec1}
============

While deficiencies in DNA repair processes are associated with cancer susceptibility as has been seen in cancer-prone syndromes such as Xeroderma pigmentosum, Ataxia Telangiectasia (AT), Nijmegen Breakage Syndrome (NBS), and Fanconi's anemia, the inhibition of DNA repair and other damage response proteins by small-molecule inhibitors can potentially be exploited to sensitize tumor cells when used in combination with chemo- and radiotherapy or in certain genetic backgrounds. Many therapies, including alkylating agents such as temozolomide (TMZ), camptothecins and radiation produce DNA single-strand breaks (SSBs) and inhibitors of poly(ADP-ribose)polymerase (PARP), an essential player in the repair of this type of DNA damage, have shown great potential as sensitizers in a variety of tumor types. This paper will briefly review the PARP family and its two most abundant members, PARP-1 and PARP-2, their role in DNA repair and other biological processes, and how PARP activity is being targeted for cancer therapy.

Background: the PARP family {#Sec2}
===========================

Poly(ADP-ribosyl)ation is a ubiquitous protein modification involved in the regulation of transcription, cell proliferation, differentiation, DNA methylation and apoptosis which modulates protein function by regulating either enzymatic activities or macromolecular interactions between proteins, DNA or RNA \[[@CR1]--[@CR3]\]. This modification is carried out by the PARPs, also known as ADP-ribosyltransferases (ADPRTs) or poly(ADP-ribose) synthetases a family of abundant eukaryotic enzymes. The family members are activated in response to different cellular stresses including transient and localized DNA strand breaks caused by a variety of biological process such as DNA repair, recombination, stalled replication forks, gene rearrangements, as well as by oxidative stress, DNA-binding drugs and in certain circumstances protein--protein interactions in the absence of DNA damage. Once activated, the enzyme rapidly catalyzes the transfer of ADP-ribose moieties from NAD^+^ to the acceptor protein resulting in the attachment of linear or branched polymers of ADP-ribose (PAR). PARP-1 itself is the primary target for poly(ADP-ribos)ylation in vivo*,* with more than 90% of PAR being found on PARP-1 \[[@CR4]\]. The modifications are heterogeneous with respect to length (from a few to 200 ADP-ribose units) and extent of branching (one branch per 20--50 ADP-ribose units). A 20 amino-acid PAR-binding motif was initially established from the analysis of several DNA-repair and checkpoint proteins \[[@CR5]\] and more recently, using proteomic approaches, a PAR-binding motif was also identified in a group of ribonucleoproteins \[[@CR6]\]. It was also shown that the structural *macro* domain is an ADP-ribose-binding module \[[@CR7]\]. Such domains have been found in macroH2A, a histone variant involved in transcriptional repression and chromosome X inactivation \[[@CR8]\] and PARP-9/BAL1, which is over-expressed in diffuse large B-cell lymphomas \[[@CR9]\]. In addition to the direct covalent modifications of proteins by their PARylation, some proteins have a high affinity for the polymers themselves and this is exploited in some settings for the control of their localization and function \[[@CR1]\].

Poly(ADP-ribosyl)ation is a dynamic process consuming substantial amounts of NAD^+^. The in vivo half-life of the polymer is \<1 min with the steady-state levels of PAR being regulated by the catalytic reactions of poly(ADP-ribose) glycohydrolase (PARG) and possibly the ADP-ribose hydrolase ARH3. ADP-ribosyl protein lyase, which cleaves the link between the first ADP-ribose and the modified amino acids, has been described in rat tissues and might also function in human cells \[[@CR10]\]. The degradation of PAR may begin immediately after the initiation of PAR synthesis and can be completed within minutes after the cessation of PAR synthesis has occurred \[[@CR4]\]. This generates large amounts of AMP that in turn activates the bioenergetic sensor AMP-activated protein kinase (AMPK).

Based on a structural homology with the catalytic domain of the PARP-1 protein 17 PARP family members have been identified using bioinformatics' approaches \[[@CR3]\]. In addition to the catalytic domain, these proteins typically contain one or more additional motifs or domains, including zinc fingers, "BRCA1 C-terminus-like" (BRCT) motifs, ankyrin repeats, macro domains and WWE domains (involved in DNA or RNA binding, protein--protein interaction or cell signaling), conferring unique properties on each PARP protein \[[@CR11]\]. The catalytic domain of PARP-1 contains three crucial residues: a histidine and a tyrosine that are important for NAD^+^ binding and a glutamic acid that is essential for polymerase activity (discussed in \[[@CR10]\]). This latter residue has been replaced in PARPs 6--16 and raises the question as to whether these proteins have poly- or mono-(ADP-ribosyl)ating activity. For instance PARP-10 has transferase rather than polymerase activity \[[@CR12]\]. A tentative classification of PARP-family members has been proposed according to their putative functional domains or established functions: DNA-dependent PARPs (PARP-1 and PARP-2), tankyrases, CCCH-type zinc-finger PARPs, and macroPARPS \[[@CR3]\]. Indeed among the 17 members of the PARP family, PARP-1 and PARP-2 are the only ones reported until now to be highly stimulated by DNA damage.

PARP-1 {#Sec3}
------

PARP-1, the founding family member, is responsible for the synthesis of the majority of PAR in eukaryotic cells and after the histones, is the most abundant nuclear protein \[[@CR13]\]. The gene is located on chromosome 1q41-42 and the 113-kD human PARP-1 (hPARP-1) protein is organized into at least six domains, four of which have well-defined functions (Fig. [1](#Fig1){ref-type="fig"}). Domain A in the N-terminal region is the DNA-binding domain (DBD). Its affinity for damaged DNA is regulated by two zinc-finger motifs which are sufficient to target the entire protein to the damaged DNA \[[@CR14]\]. The two PARP-1 zinc-finger motifs are unique as they recognize altered DNA structures rather than specific sequences: they are known to recognize DNA nicks, overhangs, blunt ends, and other forms of damage \[[@CR14]--[@CR16]\]. The B domain contains a bipartite nuclear localization signal (NLS) and a caspase-3 cleavage site. The auto-modification domain D contains a BRCT motif *via* which PARP-1 participates in various protein--protein interactions. The domain F is the catalytic C-terminal region \[[@CR11]\]. This domain can be reduced to just a 40-kDa C-terminal polypeptide without losing the basal catalytic activity \[[@CR17]\]. Little is known about the function of the C and E domains. However, a third zinc domain in hPARP-1 has recently been characterized in the C domain \[[@CR18], [@CR19]\]. This region is thought to modulate the N-terminal-to-C-terminal communication that leads to the DNA-dependent activation of PARP-1 \[[@CR18]\]. Although this zinc ribbon domain does not bind DNA directly, it is necessary for DNA-stimulated activation of the full-length enzyme \[[@CR19]\]. This has been recently confirmed by structural analysis of PARP-1 complexed with damaged DNA \[[@CR20]\].Fig. 1The domain structure of the two DNA damage-dependent human PARPs, PARP-1 and PARP-2, showing the DNA-binding, the automodification and catalytic domains (domains *A*--*F*). The PARP signature sequence (in *dark blue* within the *F* catalytic domain) is the most conserved between the PARPs*. Zn I* and *Zn II*: Zinc-finger motifs. *Zn III*: Zinc ribbon domain*. NLS* nuclear localization signal; *BRCT* BRCA1 carboxy terminus; *NoLS* nucleolar localization signal

Under normal conditions, PARP-1 is associated with histones, DNA, and other chromatin-associated factors \[[@CR21]\]. Recently, it has been shown that the auto-modification of PARP-1 mediates its tight binding to the nuclear matrix in rat liver cells, creating two PARP-1 pools, and that this binding is accompanied by increased PARP-1 activity \[[@CR22]\].

Expression patterns and genetic variation {#Sec4}
-----------------------------------------

PARP-1 and PARP-2 expression and activity have been assessed in a variety of different cells and tissues. Grube and Bürkle \[[@CR23]\] compared PARP activities in purified leukocytes from 13 mammalian species and found a strong correlation between activity and lifespan with human cells displaying approximately five times the activity of rat cells. Intra-species comparisons revealed a decline in activity with age for PARP-1 and PARP-2 but interestingly no correlation between protein levels and enzymatic activity (reviewed in \[[@CR24]\]). The presence of sequence variants, such as single nucleotide polymorphism (SNPs), in DNA damage detection and repair genes has been associated with altered cancer risk and responses to therapy treatment through the modulation of enzymatic activity in some cases. Five SNPs with a variant allele frequency \>5% have been reported in the SNP500 study populations within the coding region of the PARP-1 gene (<http://snp500cancer.nci.nih.gov/snplist.cfm>). These include the Val762Ala variant (c.2285T \> C rs1136410) located in exon 17 of the PARP-1 gene that has been associated with a reduced enzymatic activity \[[@CR25]--[@CR27]\] and an increased risk of developing cancers of the prostate, esophageal, lung and thyroid cancer (reviewed in \[[@CR24]\]). A micro satellite polymorphism in the promoter, consisting of a variable number of CAs, has also been identified \[[@CR28]\]. This is located close to the binding site of the Yin Yang 1 transcription factor that has been shown to stimulate poly(ADP-ribosy)lation and DNA repair \[[@CR29]--[@CR31]\]. Zaremba and colleagues \[[@CR24]\] undertook a comprehensive assessment of PARP-1 expression and activity in relation to PARP-1 SNPs in a panel of 19 solid and hematological adult and pediatric human cancer cell lines and found a wide range of PARP activity which was on average higher than the mean activity measured in normal human lymphocytes from healthy volunteers and cancer patients, and supports other observations of increased PARP activity in tumors. For example, PARP-1 expression is higher in hepatocellular carcinoma vs. normal liver tissue \[[@CR32]\]. However, no correlation was found between PARP activity and PARP-1 protein expression or an association with the status of either the Val762Ala or the (CA)n polymorphisms. Dysregulation of *PARP*-*1* gene expression has been found in a set of 35 breast carcinomas with the majority of breast tumors strongly expressing *PARP*-*1* mRNA showing an amplification of the 1q41-44 region where *PARP*-*1* is localized \[[@CR33]\]. Clearly, the regulation of PARP-1 activity is complex and needs further investigations.

PARP-1 and DNA repair {#Sec5}
---------------------

A number of *parp*-*1* knockout mice have been generated (for instance \[[@CR34]--[@CR36]\]). These animals are viable and fertile, suggesting that PARP-1 activity is not essential for viability in the absence of genotoxic stress. However, the mice and derived cells are hypersensitive to ionizing radiation and alkylating agents, such as MNNG, MNU, or MMS \[[@CR37]\]. Thus although PARP-1 appears to be dispensable for normal cellular activity, it would appear to be an essential survival factor for recovery from DNA damage. A second phenotype observed in these knockout animals is increased genomic instability. A four- to fivefold increase in the frequency of sister chromatid exchange has been reported in the PARP-1 knockout derived cells \[[@CR38]\].

In vitro, the first role that was described for PARP-1 was in the response to DNA damage. As discussed above PARP-1 is a molecular sensor of DNA strand breaks and through its ribosylating activity plays a key role in the spatial and temporal organization of their repair. The main targets for this activity are PARP-1 itself, histones H1 and H2B, high mobility group proteins (HMGP) (non-histone components of chromatin), topoisomerases I and II, DNA helicases, SSB repair (SSBR) and base-excision repair (BER) proteins and various transcription factors with proteins either directly interacting with the ADP-ribosylated PARP or via the PARs. Through its own poly(ADP-ribosyl)ation and that of histones, PARP-1 loosens the chromatin allowing access to DNA strand breaks and is also involved in the recruitment of the components of the BER/SSBR pathways \[[@CR39]\]. The automodification of PARP-1 itself promotes its interaction with XRCC1 through its BRCT domain. This leads to the recruitment of DNA polymerase β and DNA ligase III thus completing the repair of the single-strand break. PARP-1 has also been shown to be involved in human flap endonuclease 1 (FEN-1)-dependent strand displacement during DNA synthesis by DNA polymerase β \[[@CR40]\]. In addition to its role in BER, PARP-1 is involved in several other DNA damage-repair processes, including the repair of DNA double-strand breaks (DSBs). For instance, the recruitment of MRE11, NBS1, and ATM to DSBs has been reported to depend on PARP-1 activity \[[@CR41]\] and PARP-1 is a component of an alternative pathway of non-homologous end joining (NHEJ) \[[@CR42]\]. When essential components of the classical pathway of NHEJ are absent, PARP-1 is recruited for DSB repair with the ligase III and probably with histone H1 \[[@CR43]\]. The presence of poly(ADP-ribose) chains at the site of DNA damage also acts as an anti-recombinogenic factor, preventing the inappropriate recombination of homologous DNA \[[@CR44]\].

PARP-1 and chromatin structure {#Sec6}
------------------------------

In the context of the cellular response to DNA damage, histone modifications also play an important role in the recognition and accessibility of sites to the DNA-repair machinery. Early biochemical studies suggested that PARP-1 could disrupt chromatin structure by poly(ADP-ribosyl)ation of histones (mainly histone H1) and destabilization of nucleosomes \[[@CR45]--[@CR47]\]. As mentioned above, chromatin poly(ADP-ribosyl)ation leads to its decondensation, followed by the release of PARP-1 from the DNA allowing the recruitment and access of various DNA repair enzymes \[[@CR48]\].

PARP-1 binds to histones H1, H2A, and H2B. In addition, the core histones H3 and H4 are essential for PARP-1's interaction with nucleosomal particles \[[@CR49]\]. While histone H4 activates PARP-1 activity, histone H2A completely inhibits PARP-1 activity \[[@CR49]\]. Non-histone chromosomal proteins, including HMGP and the heterochromatin proteins HP1α and HP1β are also poly(ADP-ribosyl)ated \[[@CR50], [@CR51]\]. In addition to its role in DNA repair, PARP-1 also plays a role in chromatin repair after oxidative stress. Nucleosomal histones are known to protect DNA from free radical-mediated damage. This protection is dependent on nucleosome assembly and does not reflect the presence of scavenging proteins \[[@CR52]\]. Oxidatively damaged histones are able to cross-link with DNA and would impair the detachment-reassembly process. Thus, to maintain genomic integrity, the oxidized histones must be degraded by the 20S proteasome and this degradation is highly selective following oxidation. While histones H1 and H4 have the highest degradation rates, PARylated histone H2A is at the other end of the spectrum \[[@CR53]\]. The 20S proteasome is known to interact with PARylated PARP-1 leading to the specific stimulation of its proteolytic activity \[[@CR54]\]. It has been shown recently that poly(ADP-ribosyl)ation protects histones from degradation and that oxidized histones are less PARylated, making them more prone to proteosomal degradation by the activated proteasome and thus protecting the integrity of the chromatin \[[@CR55]\]. The damage-induced phosphorylation of histone variant H2AX may serve as a signal for the timely recruitment and/or retention of DNA repair and checkpoints proteins in the vicinity of DNA lesions. The H2AX-associated factors promote both integration and dissociation of H2AX and exchange with conventional H2A histone. These factors include FACT (Spt16/SSRP1), DNA-PK and PARP-1. It has been shown that FACT, involved in the H2AX exchange process, is stimulated by phosphorylation and inhibited by ADP-ribosylation \[[@CR56]\]. More recently, the chromatin remodeling enzyme ALC1 (amplified in liver cancer 1), a member of the SNF2 superfamily of ATPases, has been shown to be rapidly recruited to DNA damage sites via an interaction with poly(ADP)ribosylated PARP-1, activating its ATPase and chromatin remodeling activities and catalyzing PARP1-stimulated nucleosome sliding \[[@CR57], [@CR58]\].

The combined effects of (ADP-ribosyl)ation and other post-translational modifications have also been described. For instance (ADP-ribosyl)ation can occur on acetylated core histones and newly synthesized core histones can be reversibly acetylated and (ADP-ribosyl)ated, probably to facilitate their assembly into histone complexes and accessibility during replication \[[@CR59]\].

PARP-1 and PARG have also been shown to influence chromatin domain structure through their interaction with the NAD^+^-dependent histone-deacetylase silent information repressor protein-2 (SIR2) resulting in the silencing of specific chromosomal domains in drosophila \[[@CR60]\]. The molecular dissection of these interactions is facilitated in this model system that only has a single *Parp* gene which encodes a protein with the same domain structure as PARP-1, a single tankyrase gene and a single gene predicted to encode a PARG protein and in which *Parp* mutations are lethal and drastically alter many aspects of developmental physiology \[[@CR61]\]. The activation and ADP-ribosylation of PARP (and possibly other local chromatin proteins) loosens chromatin structure early in the silencing process and this facilitates SIR2 access to acetylated histone tails. PARG contributes to this process by degrading protein bound ADP-ribose moieties, and thus controlling SIR2 activity and localization \[[@CR60]\].

Another dimension to the regulatory functions of PARP-1 is its role in the regulation of DNA methylation patterns, gene silencing, and imprinting (reviewed by \[[@CR62]\]). CTCF, a nuclear factor involved in imprinting and insulator processes, activates PARP-1 activity inducing PARP-1 auto-modification. These polymers non-covalently interact with the DNA methyl-transferase 1 (Dnmt1), inhibiting its enzymatic activity. In the absence of PARylated PARP-1, the Dnmt1 is free to methylate DNA, whereas if the levels of PARylated PARP-1 remain high (for instance if PARG is absent), the stable inhibition of Dnmt1 would prevent DNA methylation resulting in DNA hypomethylation. It would seem that not only can PARylated PARP-1 bind Dnmt1 but it can also bind to the Dnmt1 promoter, maintaining this region unmethylated \[[@CR63]\]. Thus the deregulation of PAR levels, which is dependent on the balance between PARP and PARG activities, could have a major impact on cellular methylation patterns.

Other cellular functions of PARP-1 {#Sec7}
----------------------------------

As discussed above, PARP-1 can influence transcription and gene expression via several non-exclusive mechanisms including its histone-modifying enzymatic activity promoting the dissociation of nucleosomes and the decondensation of chromatin and regulating genome methylation patterns. In addition, PARP-1 can act through its direct interaction with transcription factors and their binding sites. PARP-1 has been shown to function as a transcriptional co-activator of NF-κB, the transcription factor that regulates immune and inflammatory response genes \[[@CR64]\].

The discovery that PARP-1 can also be activated by certain types of DNA structures, such as hairpins, cruciforms, and supercoiled DNA \[[@CR15]\], invalidated the dogma that DNA beaks are essential for its activation. Protein--protein interactions in the absence of DNA in vivo and in vitro, as reported for phosphorylated ERK2 \[[@CR65]\] and for the CCCTC-binding factor \[[@CR66]\], have also been shown to result in PARP-1 activation. The elucidation of the mechanism that leads to this activation remains to be established.

PARP-2 {#Sec8}
------

Cells derived from *parp*-*1* knockout mice were shown to be capable of synthesizing poly(ADP-ribose) in response to DNA damage \[[@CR67]\]. Such studies led to the discovery of a second DNA-damage-activated PARP, PARP-2, that is also a nuclear protein and forms PAR in response to DNA damage. The activity of PARP-2 accounts for approximately 10% of the total PARP activity of human cells \[[@CR68]\]. Mice in which the *parp*-*2* gene is deleted are viable, however if both *parp*-*1* and *parp*-2 are deleted embryonic lethality is observed, suggesting that there is some overlap in their functional activities \[[@CR69]\]. Although *Parp*-*2* knockout mice are generally less sensitive to DNA damage produced by IR than *parp*-*1* knockout mice \[[@CR69]\], *parp*-*2* knockout cells are more sensitive to doses below 2 Gy, raising the possibility that PARP-2 plays a role in the G2/M phase cell-cycle checkpoint activated in response to low doses of ionizing radiation \[[@CR70]\].

Among the PARP family members, PARP-2 is the closest relative of PARP-1 with their catalytic F-domains having approximately 69% similarity. The N-terminal domain of murine PARP-2 does not contain zinc-finger motifs but a highly basic DBD, a NLS and a nucleolar localization signal (NoLS; Fig. [1](#Fig1){ref-type="fig"}) which displays homology with the SAP domain found in various nuclear proteins like APE-1 and Ku-70, involved in chromosomal organization or DNA repair. The PARP-2 DBD is structurally different from that of PARP-1, probably reflecting differences in the DNA structures recognized by each enzyme \[[@CR11], [@CR68]\]. The PARP-2 E domain acts both as the interacting interface with various partners and as an auto-modification domain \[[@CR71]\]. The border between the E and F domains contains a caspase-8 cleavage site \[[@CR72]\].

PARP-1 and PARP-2 can homo-and hetero-dimerize and poly(ADP-ribose)ate each other \[[@CR71]\]. PARP-2 was found to interact with the BER proteins XRCC1, DNA polymerase β and DNA ligase III, all of which are PARP-1 partners \[[@CR71]\]. PARP-2 is a component of a functional BER complex in vivo, however, PARP-1 and PARP-2 were shown to accumulate with different kinetics at laser-induced DNA damaged sites, leading to an implication of PARP-2 at later steps in the BER/SSB repair process \[[@CR73]\]. PARP-2 was recently shown to be critical for PARP-1 mediated activation of homologous recombination at stalled replication forks \[[@CR74]\]. Some other specific functions have been shown for PARP-2, for instance a role in genome surveillance, the maintenance of telomere integrity, translocations during immunoglobulin class switch recombination, spermatogenesis, adipogenesis and T cell development, and the maintenance of centromeric heterochromatin integrity (reviewed in \[[@CR72]\]). PARP-2 has been proposed to play a role in the G2/M phase cell-cycle checkpoint in response to low-dose ionizing radiation, pointing to possible clinical applications of specific PARP-2 inhibitors in combination with continuous low-dose radiotherapy \[[@CR72]\].

The cellular consequences of PARP inhibition {#Sec9}
============================================

PARP inhibitors and chemopotentiation {#Sec10}
-------------------------------------

One of the first reports that a PARP inhibitor enhanced cytoxicity came 30 years ago from the group of Sydney Shall \[[@CR75]\] who demonstrated that 3-aminobenzamide (3-AB) prevented the rejoining of DNA strand breaks caused by the alkylating agent dimethyl sulphate and increased its toxicity in L1210 mouse leukemia lymphoblast cells. 3-AB is a simple analogue of nicotinamide, the other product of PARP-1 mediated catalysis of NAD^+^, itself a weak PARP inhibitor. Most inhibitors act through binding to the catalytic domain of the enzyme and thus while are specific for PARP activity, are not selective for the different members of the PARP superfamily. The benzamides are approximately 10--20 fold more potent than nicotinamide but lack the specificity and potency to be of use in preclinical and clinical studies. These observations lead several groups to embark on PARP inhibitor development programs. For instance, Banasik and colleagues \[[@CR76]\] identified a number of more potent inhibitors including 1,5-dihydroisoquinoline, 2-methyquinazolin-4-*(3H)*-one, 4-amino-1-8-napthalimide and 2-nitro-6-*(5H)*-phenanthridinone, which have been used as lead compounds for subsequent drug development and the identification of the essential features for efficient PARP inhibition through structure--activity studies (see \[[@CR77]\]). Inhibitor design has also been aided by crystallographic studies of inhibitors bound to PARP catalytic sites, such as those recently published for the catalytic domain of human PARP-2 in complex with the PARP inhibitor ABT-888 \[[@CR78]\]. The results contribute to the understanding of the structural similarities and differences that can be exploited to design more selective inhibitors but for most cross-reactivity between different members of the human PARP family is observed. These proteins share only between 18 and 45% homology in their catalytic domains, but crystal structures indicate their structure is conserved and the mode of NAD^+^ cofactor binding is very similar.

Using this rational drug design approach, more potent inhibitors have been identified and that had low toxicity and were active in combination studies with anticancer chemotherapies in xenograft models (see \[[@CR79]\]). For instance, Miknyocksli et al. \[[@CR80]\] showed that CEP-6800, a 3-amonomethyl carbazole imide inhibitor of PARP-1 and PARP-2, potentiated the antitumor activity of TMZ, irinotecan, and cisplatin against tumor xenografts in mouse, Tentori et al. \[[@CR81]\] that GP1 15427 could enhance the antitumor efficacy of TMZ against melanoma, glioblastoma multiforme, and lymphoma growing in the mouse brain, and Calabrese and colleagues found an improved therapeutic index with AG14361, an inhibitor 1,000 times more potent than 3-AB, in combination with TMZ, irinotecan, and radiation in a human colon tumor xenograft model \[[@CR82]\]. The monofunctional alkylating agent TMZ generates three major modified bases in DNA, N7-methylguanine, 3-methyladenine and O^6^-methylguanine, the latter being repaired by the O^6^-methylguanine-DNA methyltransferase (AGT). If not repaired by AGT, the mismatch repair (MMR) pathway intervenes, but as the modified base is located in the template strand, this triggers repeated cycles of MMR-mediated excision/resynthesis, which eventually leads to the generation of single-stand breaks, growth arrest, and apoptosis. The enhancement of the antitumor activity of TMZ by the presence of a PARP inhibitor comes from the blocking of BER that removes the*N*-methylpurines (reviewed in \[[@CR79]\]). However, recent data from Horton et al. \[[@CR83]\] has shown that potentiation can be found in a variety of repair backgrounds in leukemia cells. They found that while the inhibitor ABT-888 enhanced TMZ growth inhibition most effectively in MMR-deficient cells with low MGMT activity, it also potentiated TMZ activity in MMR-deficient cells with elevated MGMT activity and unexpectedly in MMR-proficient leukemia cells. Clearly the mechanistic basis of these observations needs further investigation but they do suggest that the potentiation might be independent of MGMT status opening up the possibility of using this drug combination in other clinical settings.

The first phase 1 clinical trial of a PARP inhibitor was carried out between 2003 and 2005 with AGO14699, a potent tricyclic indole inhibitor, in combination with TMZ in patients with advanced solid tumors \[[@CR84]\] and paved the way for other trials with other PARP inhibitors in combination with chemotherapeutic agents ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); recently reviewed in \[[@CR10]\] and \[[@CR85]\]). A total of 48 clinical trials involving PARP inhibitors in a cancer setting are registered: 24 phase I, 2 phase I/II, 2I phase II and one phase III study involving over 4,500 patients. The majority of these trials will combine a PARP inhibitor with standard chemotherapeutic protocols, for instance with TMZ in patients with skin and solid tumors, with the largest being a phase III trial of gemcitabine/carboplatin with or without the PARP inhibitor BS1-201 in patients with previously untreated advanced squamous cell lung cancer, the ECLIPSE trial, which has a start date of March 2010. The remaining trials are either combining PARP inhibitors with radiation or are targeting tumors, which as discussed below, are genetically predisposed to die when PARP activity is inactivated or share characteristics of such tumors.

PARP inhibitors and radiosensitization {#Sec11}
--------------------------------------

Early experimental evidence had also shown that PARP inhibitors acted as radiosensitizers in rodent cells, but their effect against human cells was often only marginal (\[[@CR86]\] and refs therein). To elucidate the origin of this apparent differential radiosensitization, our group assessed the radiation survival of a panel of human and rodent cell lines including PARP-1 repair-deficient and repair-proficient mouse 3T3 fibroblasts cell lines, in the absence and presence of the PARP inhibitor 4-amino-1,8-naphthalimide (ANI). The results suggested that radiosensitization by ANI depends primarily on the percentage of cells engaged in DNA replication. Indeed, in synchronized HeLa cells, radiosensitization by ANI was found to occur specifically in the S phase of the cell cycle \[[@CR86]\].

The consequences of PARP-1 disruption or inhibition on DNA SSBR and radio-induced lethality were further investigated in synchronized, isogenic HeLa cells stably silenced or not for PARP-1 (PARP-1-KD) or XRCC1 (XRCC1-KD) \[[@CR87]\]. PARP inhibition prevented the recruitment of XRCC1 at sites of 405 nm laser micro irradiation, slowed SSBR tenfold and triggered the accumulation of large persistent foci of PARP-1 and PCNA at photo-damaged sites which we believe hinder the recruitment of other effectors of the BER pathway. Under these experimental conditions where PARP was inhibited, radiosensitization occurs only in those cells treated in S phase (Fig. [2](#Fig2){ref-type="fig"}) due to the collision of the persisting SSBs with replication forks and the formation of a lethal DNA double strand breaks. The inhibitor used in this study, as in many, targets both PARP-1 and PARP-2 activity and thus formally a role of PARP-2 in this radiosensitization can not be ruled out. The development of inhibitors with a greater specificity for PARP-2 compared to PARP-1 and cell line models lacking just PARP-2 will allow us to address its relative contribution to this response.Fig. 2Scheme summarizing the differential effect of PARP-1 inhibition versus silencing on SSB repair via the BER pathway. The experimental evidence would suggest that SSB rejoining proceeds via the LPR sub-pathway when the SPR is deficient because of a lack of PARP-1. In contrast, inhibition of poly(ADP-ribosyl)ation in PARP-1-proficient cells was found to result in the accumulation of PARP-1 and PCNA in the vicinity of DNA damaged sites, with a tenfold reduction of the bulk rate of SSBR. This does not impact on radiosensitivity in the G1 phase of the cell cycle, probably because cells have enough time to perform SSB repair. However, under such conditions in S phase collision of unrepaired SSBs with replication forks results in a increase of radiosensitivity due to the formation of a large number of DSBs (reproduced with permission from \[[@CR87]\])

PARP-1 silencing also prevented XRCC1 recruitment to damage sites but did not lengthen the lifetime of PCNA foci and we found that PARP-1-KD and XRCC1-KD cells in S phase completed SSBR as measured by alkaline elution as rapidly as in controls, while SSBR was delayed in G1. Taken together, the data demonstrate that a PARP-1 and XRCC1-independent SSBR pathway operates when the short patch repair (SPR) branch of BER is absent. The likely mechanism is a switch from SPR to long patch repair branch as PCNA recruitment at photo-damaged sites was normal in PARP-1-KD cells (Fig. [2](#Fig2){ref-type="fig"}). PARP-1 silencing, however, under these conditions elicited hyper-radiosensitivity, which is not seen in cells in which XRCC1 is depleted (Fig. [3](#Fig3){ref-type="fig"}). As SSBR is completed in both cell types, it would suggest that some other activity of PARP-1, other than its role in SSBR, is the underlying cause of this radiation sensitivity. As discussed above, PARP-1 plays a role in the condensation of chromatin and transcriptional repression and our working model is that altered regulation of chromatin conformation following suppression of PARP-1 results in enhanced susceptibility to radiation-induced damage. However, it can not be excluded that PARP-1 plays a role in the processing of DSBs. Studies from our group had shown that the incidence and the rejoining kinetics of neocarzinostatin-induced DNA double-strand breaks was identical in PARP-1^+/+^ and PARP-1^−/−^ 3T3 cells. This would suggest that PARP-1 is not a major determinant of DNA double-strand break recovery with either strand break rejoining or cell survival as an endpoint \[[@CR88]\]. However, recent studies that investigated the activation of PARP-1 and DNA-dependent protein kinase (DNA-PK), a key player in DSB repair, by different types of DNA ends and the interaction of these two proteins in the cellular response to ionizing radiation do suggest that PARP-1 is required for a pathway that facilitates the fast repair of DNA DSBs \[[@CR89]\]. Making use of the PARP inhibitor (KU-0058684) and the DNA-PK inhibitor (NU7441) Mitchell and colleagues, found that the inactivation of the two proteins was not additive, suggesting that they co-operate within the same pathway and that they showed similar and overlapping affinities for oligonucleotides with blunt, 3′GGG or 5′GGG overhanging termini. The exact molecular mechanisms of this interaction clearly remain to be established. One possible link between PARP-1 and DNA-PK is the cyclin-dependent kinase 5 (CDK5). Identified in a synthetic lethal siRNA screen for genes that mediate sensitivity to PARP inhibitors \[[@CR90]\], CDK5 is a proline-directed serine/threonine kinase activated by the non-cyclin proteins p35 and p39. It is a very abundant protein in the nervous system and has been implicated in neurodegeneration and neurodegenerative diseases where it is believed to play a role in the changes in cell-cycle regulation which precede neuron death (for review see \[[@CR91]\]). The underlying mechanisms have been suggested to involve the inhibition of chromatin condensation as well as modulation of the activity of the DNA DSB repair protein ataxia-telangiectasia mutated (ATM) that was found to be phosphorylated by CDK5 in the nucleus of neuronal cells following exposure to camptothecin \[[@CR92]\]. O'Hare and colleagues \[[@CR93]\] showed a reduction in nuclear p35, a CDK5 cofactor, and an increase in nuclear CDK5 with increasing time of exposure to camptothecin in primary neuronal cultures suggesting that its relocation is important in the damage responses and the inhibition of CDK5 activity has also been shown to increase DNA damage-induced neuronal death \[[@CR94]\].Fig. 3Radiation survival in control, PARP-1-KD, and XRCC1-KD HeLa cells synchronized in S phase. Cells were synchronized by a double thymidine block, allowed to progress in S phase for 2 h and exposed to increasing doses of gamma rays. Following treatment, the cells were allowed to grow as colonies for 10--15 days, fixed, stained with Coomassie Blue, and then counted. The experimental data for control and XRCC1-KD lay within the same envelope of statistical deviation whereas the PARP-1-KD cells showed an enhanced radiation sensitivity (reproduced with permission from \[[@CR87]\])

Turner and colleagues showed that CDK5 functions in the DNA damage response in human breast cancer cells. In these cells, CDK5 silencing induced spontaneous formation of DNA DSBs and an increased sensitivity to camptothecin \[[@CR90]\]. Additionally, an increase in endogenous CDK5 activity after irradiation was observed in this cell type. They hypothesized that the mechanism of sensitivity to PARP inhibitor is a failure of the G2/M cell-cycle checkpoint. It is possible that in the presence of greatly increased level of SSBs, failure of this checkpoint leads to replication fork collapse and subsequent cell death. Interestingly, both ATM and PARP-1 have been shown to be phosphorylated by CDK5 together with other factors implicated in chromatin modifications \[[@CR95]\]. Therefore, based on these observations an alternative hypothesis for the increased radiation sensitivity seen in the absence of PARP-1 is via a link with CDK5 and through it a modulation of DSB repair and activation of cell-cycle checkpoints.

The implication of these results is that both the absence of PARP-1 and the inhibition of PARP activity will enhance the cytoxicity of radiotherapy particularly in rapidly dividing tumors and this working hypothesis has been supported by results from a number of groups using different PARP inhibitors and experimental models. Chalmers and colleagues showed that the PARP-1 and PARP-2 inhibitor KU-0059436/AZD2281/olaprib increases the radiosensitivity of human glioma cell lines by a replication-dependent mechanism that generates persistent DSBs \[[@CR96]\]. They have since shown that the simultaneous inhibition of homologous recombination further enhances the radiosensitizing effect of PARP inhibitors in replicating human glioma cells. The inhibition of the chaperone protein heat shock protein 90 results in the downregulation of BRCA2 and Rad51 protein levels and additive radiosensitization was observed \[[@CR97]\]. Whether the radiation sensitivity observed when a PARP inhibitor is combined with radiation is exclusively due to compromised SSBR that results in an increase in DSBs or whether DSB repair is also modulated remains to be fully established. The PARP inhibitor E7016 (formerly known as GPI21016) has also been shown to enhance tumor cell radiosensitivity in vitro and in vivo and enhanced growth delay seen with the addition of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug combination in the treatment of glioblastoma multiforme \[[@CR98]\]*.* Preclinical data showing an enhancement of the response of tumor cells to radiation has now been documented for several PARP inhibitors including AG14361 \[[@CR82]\], ABT-888 \[[@CR99], [@CR100]\], INO-1001 \[[@CR101]\], and radiosensitization of human and rodent cell lines by INO-1001 and GPI15427 (MGI Pharma) \[[@CR102]\] has been reported. These preclinical studies have lead to date to the start of three phase I clinical trials which will evaluate the safety of PARP inhibitors in addition to radiotherapy. One will test ABT-888 in combination with whole-brain radiation therapy in subjects with brain metastases. The two others will test either ABT-888 or BSI-201 in combination with TMZ and radiation therapy in subjects with newly diagnosed glioblastoma.

PARP inhibitors as single therapeutic agents {#Sec12}
--------------------------------------------

In 2005, the groups of Ashworth and Helleday \[[@CR103], [@CR104]\] showed preclinically that BRCA1 and BRCA2-deficient cells, in which the homologous recombination DSB repair pathway was compromised, were hypersensitive to the blockade of SSB repair by inhibition of PARP activity and demonstrated for the first time the potential use of PARP inhibitors as single therapeutic agents. The mechanistic basis of this cytoxicity is that blocking SSB repair leads to the formation of DSBs at the replication forks. In normal or heterozygote cells, the intact DSB repair can process these lethal lesions, but DSB repair is compromised in tumor cells that have lost the remaining *BRCA1* or *BRCA2* wild-type allele. The loss of both SSB and DSB repair pathways causes cell death. This is an example of the concept of synthetic lethality, defined as the situation when mutation in either of two genes individually has no effect but combining the mutations leads to death, that is proving to be a promising approach in the development of cancer treatments.

A number of clinical trials have been initiated to test the efficacy of this approach. The orally active PARP inhibitor olaparib (previously known as KU0059436) was tested in a phase 1 trial in a study population of 60 patients that was enriched for carriers of a *BRCA1* or*BRCA2* mutation \[[@CR105]\]. The trial showed that olaparib had an acceptable side-effect profile and did not have the toxic effects commonly associated with conventional chemotherapy. Pharmacokinetic data indicated rapid absorption and elimination and pharmacodynamic studies confirmed PARP inhibition in surrogate samples and tumor tissues and a clinical benefit was observed but only in mutation carriers. Over 650 individuals will be included in the registered phase I and II trials of PARP inhibitors as a single agent for the treatment of breast, ovarian, prostate and pancreatic cancers in *BRCA1* and *BRCA2* mutation carriers, which are underway or in the planning stages ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); recently reviewed by \[[@CR106]\]).

Effective HR requires many proteins and this opens the possibility that synthetic lethality can be achieved in pathological settings where other components of the HR pathway are lacking through germline and/or somatic mutations or via other mechanisms that control protein expression in combination with PARP inhibitors. For example, recent results from Mendes-Pereira et al. \[[@CR107]\] have shown that cells harboring PTEN mutations are sensitive to PARP inhibitors. Similarly, ATM deficiency, which is often found in mantle cell lymphoma, confers sensitivity to PARP inhibitors \[[@CR108]\].

PARP inhibitors in other clinical settings {#Sec13}
------------------------------------------

As discussed \[[@CR109]\], PARP-1 functions as a double-edged sword: on the one hand, activation of PARP is essential for DNA repair, but on the other hand, over-activation represents an important mechanism of tissue damage in various pathological conditions associated with oxidative and nitrosative stress, including myocardial reperfusion injury, heart transplantation, and autoimmune B-cell destruction associated with diabetes mellitus and hepatic injury. Continuous or excessive activation of PARP produces a depletion of NAD^+^ and ATP, slowing glycolysis and mitochondrial respiration, which could eventually lead to cellular dysfunction and necrotic cell death. PARP activation also has consequences on the transcriptional regulation of several proteins including other transcriptional factors, such as NF-κB, implicated in inflammation. The beneficial effects of the inhibition of PARP have been demonstrated in a number of cardiovascular situations and there is considerable expectation that the use of PARP inhibitors will be an efficient therapy (see recent reviews by \[[@CR109]--[@CR112]\]).

Recently, Quiles-Perez et al. \[[@CR32]\] have shown that PARP inhibition is capable of controlling hepatocellular carcinoma xenograft growth, protected against diethylnitrosamine-induced hepato-carcinogenesis and prevented tumor vasculogenesis by transcriptional regulation of both transcription factors and the expression of genes involved in tumor progression. These changes in the tumor microenvironment brought about by PARP inhibition can also have an impact on responses to radiotherapy and drug delivery. Vasoactivity has been reported for the PARP inhibitors AG14361 \[[@CR82]\] and AG0014699 (Pfizer Oncology) \[[@CR113]\] and differences were noted between the chemopotentiating effect of AG0014699 in vitro and in vivo models: the sensitivity of SW620 cells to TMZ was not enhanced by AG0014699 in vitro but in vivo the combination of AG0014699 and TMZ gave rise to pronounced tumor growth delays at doses of TMZ that alone gave only transient delays. Another tumor microenvironment that influences the chemo- and radioresistance of tumors is hypoxia. Hypoxic cells are 2.5 to threefold more radioresistant than oxic cells and intra-tumoral hypoxia can be a significant cause of treatment failure after radical radiotherapy. The group of Bristow \[[@CR114]\] hypothesized that PARP inhibition may be useful in radiosensitizing hypoxic tumor cells, which they demonstrated using in vitro models and the inhibitor ABT-888, making these agents attractive adjuncts for radiotherapy *via* mechanisms other than the inhibition of DNA repair.

Conclusions {#Sec14}
===========

There is a growing body of literature and editorials documenting and discussing the impact of PARP inhibitors as effective chemo- and radiopotentiation agents and, in BRCA-deficient tumors, as single-agent therapies. Clearly, their potential has caught the attention of researchers and industrialists, but there are many aspects of their use that still need to be established. For instance, PARP inhibitor-chemotherapy drug combinations for different tumor types remain to be fully optimized, as does the dose and schedule to maximize efficacy while minimizing side-effects. The same considerations apply to using PARP inhibitors to potentiate the effects of radiotherapy, where the complex interaction of dose and schedule may also influence the risk of developing adverse secondary reactions such as radiation-induced fibrosis and secondary cancers. Emerging evidence suggests that many sporadic tumors display a certain degree of "BRCAness" \[[@CR115]\], that is they share expression profiles that are found in tumors from *BRCA1* and *BRCA2* mutation carriers. The phenotypic similarities between some "triple-negative" breast cancers and the most prevalent type of breast cancer seen in *BRCA1* mutation carriers has lead to suggestions that these difficult-to-treat breast tumors would be sensitive to PARP inhibition (recently reviewed in \[[@CR116]\]). Indeed there are five registered clinical trails in which this will be assessed and preliminary results from a phase II trial presented at ASCO and reported in JNCI \[[@CR117]\] are very encouraging. The challenge remains to identify those subgroups of patients who could benefit from single-agent PARP inhibition.

The development of resistance to targeted therapy must also be considered. PARP-inhibitor-resistant clones have been derived from the human BRCA2-deficient cell line CAPAN1 by a deletion of a mutation in *BRCA2* \[[@CR118]\]. A similar mechanism seems to be associated with carboplatin resistance in some *BRCA2* mutation carriers with ovarian cancer (reviewed in \[[@CR119]\]). Whether all mutations will revert at the same frequency remains to be established, but this eventuality has to be taken into consideration when determining treatment options. Over the last decade, certain biological functions and the mode of action of some of the PARP family members have been deciphered, however, it has become increasingly clear that family members participate in a wide range of cellular processes. For instance, PARP-1 not only plays a role in DNA repair but is an important transcriptional activator, and in particular of the NF-κB stress-inducible transcription factors. What the long-term effects are on cellular homeostasis, including the epigenetic control of gene expression, of the inhibition of PARP activity and deciphering how this might impact long-term therapeutic responses will be a challenge for the next decade.
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